Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC

June 03, 2020 By The ASCO Post Staff

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in other VHL-related lesions (Abstract 5003).

Related Content